These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 23466583)

  • 21. Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for head and neck cancer.
    Cannon DM; Lee NY
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):660-5. PubMed ID: 18037580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensity modulated radiotherapy improves target coverage and parotid gland sparing when delivering total mucosal irradiation in patients with squamous cell carcinoma of head and neck of unknown primary site.
    Bhide S; Clark C; Harrington K; Nutting CM
    Med Dosim; 2007; 32(3):188-95. PubMed ID: 17707198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis.
    Sher DJ; Neville BA; Chen AB; Schrag D
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e197-206. PubMed ID: 21596483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Total Mucosal Irradiation with Intensity-modulated Radiotherapy in Patients with Head and Neck Carcinoma of Unknown Primary: A Pooled Analysis of Two Prospective Studies.
    Richards TM; Bhide SA; Miah AB; Del Rosario L; Bodla S; Thway K; Gujral DM; Rooney KP; Schick U; McGovern T; Grove L; Newbold KL; Harrington KJ; Nutting CM
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e77-e84. PubMed ID: 27180092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer.
    Huang J; Baschnagel AM; Chen P; Gustafson G; Jaiyesmi I; Folbe M; Ye H; Akervall J; Krauss D
    Int J Clin Oncol; 2014 Apr; 19(2):240-6. PubMed ID: 23479120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.
    McCloskey SA; Jaggernauth W; Rigual NR; Hicks WL; Popat SR; Sullivan M; Mashtare TL; Khan MK; Loree TR; Singh AK
    Am J Clin Oncol; 2009 Dec; 32(6):587-91. PubMed ID: 19581794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: Long-term results.
    Ghosh-Laskar S; Yathiraj PH; Dutta D; Rangarajan V; Purandare N; Gupta T; Budrukkar A; Murthy V; Kannan S; Agarwal JP
    Head Neck; 2016 Apr; 38 Suppl 1():E1481-7. PubMed ID: 26561342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensity modulated arc therapy implementation in a three phase adaptive (18)F-FDG-PET voxel intensity-based planning strategy for head-and-neck cancer.
    Berwouts D; Olteanu LA; Speleers B; Duprez F; Madani I; Vercauteren T; De Neve W; De Gersem W
    Radiat Oncol; 2016 Apr; 11():52. PubMed ID: 27039294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unknown primary head and neck squamous cell carcinoma in the era of fluorodeoxyglucose-positron emission tomography/CT and intensity-modulated radiotherapy.
    de Ridder M; Klop M; Hamming-Vrieze O; de Boer J; Jasperse B; Smit L; Vogel W; van den Brekel M; Al-Mamgani A
    Head Neck; 2017 Jul; 39(7):1382-1391. PubMed ID: 28370570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved survival using intensity-modulated radiation therapy in head and neck cancers: a SEER-Medicare analysis.
    Beadle BM; Liao KP; Elting LS; Buchholz TA; Ang KK; Garden AS; Guadagnolo BA
    Cancer; 2014 Mar; 120(5):702-10. PubMed ID: 24421077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for anal cancer.
    Hodges JC; Beg MS; Das P; Meyer J
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):773-83. PubMed ID: 24726392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclical hypofractionated radiotherapy also known as "QUAD Shot" alone using intensity-modulated radiotherapy for squamous cell carcinoma of the parotid gland in an 85-year-old patient with multiple comorbidities.
    Kil WJ; Camphausen K
    Head Neck; 2017 Apr; 39(4):E55-E60. PubMed ID: 28170130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma.
    Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
    PLoS One; 2018; 13(7):e0200137. PubMed ID: 29979726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Intensity-Modulated Radiotherapy on Health Care Costs of Patients With Anal Squamous Cell Carcinoma.
    Chin AL; Pollom EL; Qian Y; Koong AC; Chang DT
    J Oncol Pract; 2017 Dec; 13(12):e992-e1001. PubMed ID: 29035618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life among long-term survivors of head and neck cancer treated by intensity-modulated radiotherapy.
    Chen AM; Daly ME; Farwell DG; Vazquez E; Courquin J; Lau DH; Purdy JA
    JAMA Otolaryngol Head Neck Surg; 2014 Feb; 140(2):129-33. PubMed ID: 24337483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective evaluation of Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost (IMRT-SIB) in head and neck squamous cell carcinoma in patients not suitable for chemo-radiotherapy.
    Rastogi M; Sapru S; Gupta P; Gandhi AK; Mishra SP; Srivastava AK; Khurana R; Hadi R; Sahni K; S F
    Oral Oncol; 2017 Apr; 67():10-16. PubMed ID: 28351562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dosimetry audit for a multi-centre IMRT head and neck trial.
    Clark CH; Hansen VN; Chantler H; Edwards C; James HV; Webster G; Miles EA; Guerrero Urbano MT; Bhide SA; Bidmead AM; Nutting CM;
    Radiother Oncol; 2009 Oct; 93(1):102-8. PubMed ID: 19596158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protons in head-and-neck cancer: bridging the gap of evidence.
    Ramaekers BL; Grutters JP; Pijls-Johannesma M; Lambin P; Joore MA; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1282-8. PubMed ID: 23273998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report.
    Yao M; Graham MM; Smith RB; Dornfeld KJ; Skwarchuk M; Hoffman HT; Funk GF; Graham SM; Menda Y; Buatti JM
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1410-8. PubMed ID: 15590172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.